Search clinical trials for: Tyrosine

Total 1135 results

Novartis Pharmaceuticals

Completed

A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

Chronic Myelogenous Leukemia | Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Germany, Australia, Netherlands, Spain, Korea, Republic of, France, Japan, Italy, Singapore, United States
Moorfields Eye Hospital NHS Foundation Trust
Peschke Meditrade, GmbH

Completed

Corneal Collagen Cross-linking With Hypotonic Riboflavin in Corneas Thinner Than 400 Microns (HypotonicRibo)

Keratoconus

United Kingdom
Haihua Yang

Unknown

Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Early Stereotactic Body Radiation Therapy to the Primary Tumor in Advanced Non-small Cell Lung Cancer

Advanced Non-small Cell Lung Cancer

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Takeda; Amgen

Recruiting

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | t(9;22) | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | BCR-ABL1...

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | High Risk Myelodysplastic Syndrome | Recurrent Acute Biphenotypic Leukemia | Blasts 20 Percent or More of Bone Marrow Nucleated Cells | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk...

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Chronic Myelomonocytic Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic Syndrome

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Untreated Adult Acute Myeloid Leukemia

United States
University of Southern California
National Cancer Institute (NCI); Vasgene Therapeutics, Inc; Whittier Foundation

Terminated

EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Philadelphia Chromosome Positive | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia and other conditions

United States
National Cancer Institute (NCI)

Completed

Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia

United States
Mayo Clinic

Not yet recruiting

Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

Chronic Graft Versus Host Disease | Hematopoietic and Lymphatic System Neoplasm

United States
Jeeyun Lee

Not yet recruiting

Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer

Stomach Neoplasm
AstraZeneca

Recruiting

A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma (TrAVeRse)

Mantle Cell Lymphoma (MCL)

Canada, Poland, United Kingdom, United States, Brazil, Spain, Australia
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib

Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia

United States
National Cancer Institute (NCI)

Completed

Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors

Solid Tumors

United States
Bristol-Myers Squibb
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma

Intraocular Melanoma | Melanoma (Skin)

United States
Regeneron Pharmaceuticals

Completed

Study of Fasinumab (REGN475) in Healthy Japanese and Caucasian Subjects

Healthy Volunteers

United States
Convalife (Shanghai) Co., Ltd.

Not yet recruiting

Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases

Her2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastasis
H. Lee Moffitt Cancer Center and Research Institute
BeiGene, Ltd.

Recruiting

Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

Follicular Lymphoma | Marginal Zone Lymphoma | B-Cell Lymphoma

United States
Sundeep Khosla, M.D.

Active, not recruiting

Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans

Healthy

United States
National Cancer Institute (NCI)

Active, not recruiting

Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer

Recurrent Lung Non-Small Cell Carcinoma | Stage IV Lung Non-Small Cell Cancer AJCC v7

United States
Sun Yat-sen University

Unknown

Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection

Hepatitis B, Chronic

China
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
Texas A&M University
Philips Healthcare; US Department of Defense - Defense Threat Reduction Agency

Completed

Persistent Readiness Through Early Prediction Immunization Study (PREP DOD)

Inflammatory Response

United States
University of Southern California
National Cancer Institute (NCI)

Terminated

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Intraocular Melanoma | Melanoma (Skin)

United States
National Cancer Institute (NCI)

Suspended

Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

FLT3 Gene Mutation Negative | FLT3 Internal Tandem Duplication Positive | Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic...

United States
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Terminated

Immunotoxin Therapy and Cytarabine in Treating Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Recurrent Adult Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia

United States
National Cancer Institute (NCI)

Active, not recruiting

Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma

Gliosarcoma | Recurrent Glioblastoma | Anaplastic Astrocytoma | Anaplastic Ependymoma | Anaplastic Oligodendroglioma | Mixed Glioma | Recurrent Adult Brain Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma

Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Cutaneous Melanoma

United States
OMER B ABDELBASIT

Completed

Fetal and Neonatal Thyroid in Pregnancies With Severe Acute Respiratory Syndrome Coronavirus 2 ( SARS- COV2 ) COVID-19 (COVID-19)

Hypothyroidism | Hyperthyroidism | Thyroid Dysfunction

Saudi Arabia
Daiichi Sankyo
Merck Sharp & Dohme LLC; AstraZeneca

Recruiting

HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC)

United States, Korea, Republic of, Taiwan, Japan
AstraZeneca

Recruiting

A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer (NeoADAURA)

Non-Small Cell Lung Cancer

China, United States, Chile, Vietnam, Thailand, Brazil, Bulgaria, Canada, Germany, India, Japan, Korea, Republic of, Poland, Russian Federation, Singapore, Turkey, Austria, Israel, Spain, Taiwan, Mexico, France, Italy, Peru, Switzerland, United...
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma and other conditions

United States
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver

Hepatocellular Carcinoma | Cirrhosis

United States
University of California, San Diego
Pharmacyclics LLC.

Active, not recruiting

Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC

Head and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck

United States
Novartis Pharmaceuticals

Terminated

Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy (GEOMETRY-E)

Carcinoma, Non-Small-Cell Lung

Japan, Korea, Republic of, Singapore
Narendranath Epperla

Withdrawn

Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Recurrent Marginal Zone Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Refractory Marginal Zone Lymphoma | Refractory Nodal Marginal Zone Lymphoma | Recurrent Nodal Marginal Zone Lymphoma | Recurrent Splenic Marginal Zone Lymphoma | Refractory Splenic Marginal Zone Lymphoma and other conditions
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077)

Hepatitis C
Oslo University Hospital

Terminated

Whole Brain Radiation With or Without Erlotinib for Brain Metastases From Non-Small Cell Lung Cancer (RadEr)

Cancer

Norway
AstraZeneca

Recruiting

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment (SAFFRON)

Carcinoma | Non-Small-Cell Lung

China, Israel, Spain, United States, Canada, Italy, Korea, Republic of, Belgium, Bulgaria, Vietnam, Japan, United Kingdom, Brazil, France, Philippines, Taiwan, Thailand, Germany, Poland, Austria, Greece, Turkey, Argentina, Hong Kong, Chile and more
Novartis Pharmaceuticals

Recruiting

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

Myeloid Leukemia, Philadelphia Positive

Korea, Republic of, Germany, France, United States, Greece, Hungary, Italy, Japan, Poland, Russian Federation, Thailand, Turkey, China, Netherlands
National Cancer Institute (NCI)

Active, not recruiting

Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia

Chronic Myeloid Leukemia, BCR-ABL1 Positive

United States, Canada
Janssen Research & Development, LLC
Pharmacyclics LLC.

Active, not recruiting

A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States, France, Poland, United Kingdom, China, Belgium, Germany, Taiwan, Spain, Argentina, Israel, Turkey, Ukraine, Japan, Canada, Greece, Korea, Republic of, Netherlands, Brazil, Russian Federation, Puerto Rico, Australia, I... and more
Loxo Oncology, Inc.
Eli Lilly and Company

Active, not recruiting

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

B-cell Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Korea, Republic of, Australia, Japan, United Kingdom, Italy, Poland, France, Switzerland, Sweden
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; Boehringer Ingelheim

Completed

Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

Lung Cancer | Non-small Cell Lung Cancer (NSCLC)

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
Celgene Corporation

Terminated

Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer

Inflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast Cancer

United States
SciClone Pharmaceuticals

Unknown

First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy

EGFR Mutation Positive Non Small Cell Lung Cancer

Italy
Xiuning Le
M.D. Anderson Cancer Center; Eli Lilly and Company

Active, not recruiting

Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer | Metastatic Cancer | Advanced Cancer | EGFR Gene Mutation

United States
Mayo Clinic

Enrolling by invitation

Senescence in Chronic Kidney Disease

Chronic Kidney Disease

United States
Children's Oncology Group
National Cancer Institute (NCI); Pfizer

Completed

Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Refractory Neuroblastoma | Refractory Anaplastic Large Cell Lymphoma | Recurrent Childhood Anaplastic Large Cell Lymphoma

United States, Canada

Search clinical trials for: Tyrosine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations